PDS Biotechnology (NASDAQ:PDSB) Posts Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• PDS Biotechnology reported quarterly earnings of ($0.21) per share, exceeding analysts' estimates by $0.03.
• Shares of PDSB fell by 5.7%, closing at $1.16, with a trading volume of 800,569 shares.
• Analysts have diverse opinions on the stock, with one firm maintaining a "buy" rating and a price target of $13.00, while another downgraded it from "hold" to "sell."

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.03, Zacks reports.

PDS Biotechnology Stock Up 1.7%

PDSB traded up $0.02 during mid-day trading on Monday, reaching $1.21. 241,430 shares of the stock were exchanged, compared to its average volume of 539,498. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.92 and a current ratio of 2.92. The stock has a market capitalization of $56.42 million, a PE ratio of -1.32 and a beta of 0.95. The company has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.32. PDS Biotechnology has a 1 year low of $0.85 and a 1 year high of $4.29.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of PDS Biotechnology in a research report on Tuesday, July 1st.

Hedge Funds Weigh In On PDS Biotechnology

A hedge fund recently bought a new stake in PDS Biotechnology stock. Marshall Wace LLP acquired a new position in shares of PDS Biotechnology Corporation (NASDAQ:PDSB - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 68,454 shares of the company's stock, valued at approximately $91,000. Marshall Wace LLP owned about 0.15% of PDS Biotechnology at the end of the most recent reporting period. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.